Analyst sentiment around ADMA Biologics (ADMA) has turned more positive, with a consensus Strong Buy rating and upward revisions to earnings estimates. This has drawn fresh attention to the stock and its recent share price performance.

Despite the recent analyst optimism, ADMA Biologics' 1 day share price return of a 4.66% decline and 7 day share price return of a 9.6% decline add to a year to date share price return of a 19.91% decline. However, the 3 year total shareholder return is roughly 4x, suggesting long term holders have still seen very strong gains even as short term momentum has cooled.

If you are reassessing your biotech exposure after ADMA's recent pullback, it could be worth scanning for other healthcare names with similar potential in 36 healthcare AI stocks

So with ADMA trading at a discount of about 68.6% to an estimated intrinsic value and roughly 79.2% to the average analyst price target, is this a genuine mispricing, or is the market already weighing future growth risks correctly?

Most Popular Narrative: 31.6% Undervalued

According to the most widely followed narrative, ADMA Biologics' fair value of $20.93 sits well above the last close at $14.32, which frames the recent pullback in a very different light.

Reverse discounted cashflow at current TTM revenue of 383 MUSD at 35% FCF, 134 MUSD, revenue needs to grow 16%/y over next 10 years to justify current price (if ADMA gets to 1 BUSD of revenue by 2029, growth of 21%/year), currently undervalued

Curious what earnings profile and margin path sit behind that valuation gap, and how the narrative gets comfortable with those growth assumptions and discount rate.

Result: Fair Value of $20.93 (UNDERVALUED)

However, this hinges on ADMA sustaining its current revenue and net income profile, and on management execution in plasma sourcing and yield improvements not falling short.

Another View: Market Ratios Point To A Richer Price

While the user narrative leans on future cash flows to call ADMA roughly 31.6% undervalued, the current P/E ratio of 23.2x tells a different story. It sits above the Biotechs industry average of 16.7x, the peer average of 22.8x, and even the fair ratio of 21.6x that the market could move towards.

That premium suggests less of a clear bargain and more of a situation where expectations are already built into the price. The key question is whether you think ADMA's execution and earnings path justify paying above those benchmarks or not.

Next Steps

Sentiment in this article has been mixed, so do not wait for the crowd to decide for you. Instead, weigh the trade off between risks and potential rewards by checking the 2 key rewards and 2 important warning signs

Looking for more investment ideas?

If ADMA has you rethinking your approach, do not stop here. Broaden your watchlist with targeted ideas that match different risk, income, and quality profiles.

• Target potential mispricing by scanning for 54 high quality undervalued stocks that combine attractive prices with solid underlying metrics.
• Strengthen your income stream by reviewing 13 dividend fortresses built around higher yield opportunities that still focus on resilience.
• Prioritise resilience by checking 71 resilient stocks with low risk scores designed to spotlight companies with more stable risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.